共 132 条
[1]
Jung KW(2013)Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010 Cancer Res Treat Off J Korean Cancer Assoc 45 1-14
[2]
Won YJ(2010)Multiple myeloma Ann Oncol Off J Eur Soc Med Oncol ESMO 21 vii143-vii150
[3]
Kong HJ(2006)Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib J Clin Oncol Off J Am Soc Clin Oncol 24 3113-3120
[4]
Oh CM(2006)A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma Int J Hematol 83 309-313
[5]
Seo HG(2011)Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol 12 431-440
[6]
Lee JS(2006)Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics Clin Pharmacokinet 45 957-964
[7]
Dimopoulos MA(1988)Increased prevalence of neurologic complications among insulin dependent diabetic patients of Algerian origin Diabete Metab 14 706-711
[8]
Terpos E(2002)Genetic and environmental regulation of Na/K adenosine triphosphatase activity in diabetic patients Metab, Clin Exp 51 284-291
[9]
Richardson PG(2009)Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Leukemia 23 3-9
[10]
Briemberg H(2013)Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen Eur J Haematol 90 157-161